Document 2729
 DOCN  M94A2729
 TI    Cross reactivity of the HTLV-I, HTLV-II, HIV-1 positive sera with
       heterologous synthetic peptides.
 DT    9412
 AU    Rasulee A; Rasulee S; Klepikov N; Andreev S; Mescheryakova D; Tarasova
       S; Gurtsevitch V; Co-operative BIOLAM, Cancer Research Center, Moscow,
       Russia.
 SO    Int Conf AIDS. 1994 Aug 7-12;10(1):238 (abstract no. PB0382). Unique
       Identifier : AIDSLINE ICA10/94369846
 AB    OBJECTIVE: To study the cross reactivity of the positive sera (+S) from
       HTLV-I, -II, and HIV-1 monoinfected patients with the synthetic peptides
       (SP) corresponding to immunodominant B-epitopes of human retroviruses.
       METHODS: 40 HTLV-I, 5 HTLV-II, and 25 HIV-1 +S were tested in ELISA with
       12 SP from 9 structural protein regions of the HTLV-I, HIV-1, and HIV-2.
       RESULTS: It was found that 3%-5% HTLV-I +S weakly cross reacted with
       HIV-1 SP (301-323 and 495-516 gp120 env, 584-612 and 602-624 gp41 env).
       Similarly, 8% HIV-1 +S interacted with HTLV-I SP (100-130 p19 gag,
       376-392 and 381-400 gp21 env). One of the HTLV-II +S recognized two
       HTLV-I SP (100-130 p19 gag and 381-400 gp21 env) and one HIV-1 SP
       (495-516 gp120 env). Moreover, 13% and 42% HIV-1 +S respectively
       strongly and weakly cross reacted with HIV-2 SP (581-603 gp36 env). No
       one of the heterologous +S bound with HIV-1 SP (330-363 p24 gag), and
       HTLV-I SP (120-130 p19 gag, 176-201 and 291-312 gp46 env). CONCLUSION:
       Demonstrated cross reactivity must be taken into account in
       type-specific SP diagnostics of retroviral infections. Study of the
       aminoacid similarity between cross reactive SP and immunodominant
       domains of heterologous retroviruses are in progress.
 DE    Cross Reactions/*IMMUNOLOGY  Human  HIV
       Seropositivity/*DIAGNOSIS/IMMUNOLOGY  HIV-1/*IMMUNOLOGY
       HTLV-I/*IMMUNOLOGY  HTLV-I Infections/*DIAGNOSIS/IMMUNOLOGY
       HTLV-II/*IMMUNOLOGY  HTLV-II Infections/*DIAGNOSIS/IMMUNOLOGY
       Peptides/*IMMUNOLOGY  Predictive Value of Tests  MEETING ABSTRACT

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).